Gastric varices (GVs) are a major complication of portal hypertension in patients with liver cirrhosis. The mortality rate associated with the bleeding from GVs is not low. Balloonoccluded retrograde transvenous obliteration (BRTO) was first introduced by Kanagawa et al. as a treatment for isolated GVs in 1994. It has been performed most frequently in Asia, especially in Japan. Ethanolamine oleate was the original sclerosant used in the therapy. Since the late 2000s, BRTO using sodium tetradecyl sulfate foam or polidocanol foam as a sclerosant has been performed in many countries other than Japan. Then, early in the 2010s, modified BRTO techniques including vascular plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration were developed as an alternative treatment for GVs. This article provides a historical overview of BRTO using various sclerosants and modified BRTO techniques, such as plug-assisted retrograde transvenous obliteration and coil-assisted retrograde transvenous obliteration.
Introduction
The mortality rate associated with bleeding from gastric varices (GVs) ranges from 25% to 55%. [1] [2] [3] GVs are classified based on their location in the stomach and relationship with esophageal varices (EVs). 1 The most common type is Type 1 (GOV1) varices, which extend along the lesser curvature. It is considered as an extension of EVs and should be managed similarly to EVs with no coexisting GVs. Type 2 (GOV2) varices, which extend along the fundus, are also considered as an extension of EVs. Isolated GVs (IGV) occur in the absence of EVs, are frequently found to be located in the fundus, and tend to be tortuous and complex.
Transjugular intrahepatic portosystemic shunt (TIPS) has been adapted, to patients who underwent GV treatments, for many years to prevent rebleeding. [4] [5] [6] [7] However, regardless of the GV embolization existence, creating TIPS does not always result in complete regression of the GVs. 8 Furthermore, TIPS creation cannot always be selected as the first-line therapy due to the possible aggravation of hepatic encephalopathy. [9] [10] [11] Endoscopic injection sclerotherapy, using ethanolamine oleate (EO) as a sclerosant, was first introduced for the treatment of EVs. It was considered to be an effective therapy for the management of EVs. 12, 13 Conversely, endoscopic injection sclerotherapy was considered infeasible to treat IGVs because the blood flow is abundant in GV. Several endoscopic variceal obturation studies with cyanoacrylate or n-butyl-2-cyanoacrylate initially controlled active bleeding successfully (87% to 100%) compared with endoscopic variceal ligation (45% to 93.3%). However, the postprocedure rebleeding rates were significant, ranging from 0% to 31% at 1 year at post-procedure. [14] [15] [16] [17] Balloon-occluded retrograde transvenous obliteration involves occlusion of outflow vein in the portosystemic shunt such as a gastrorenal shunt, which is conducted by applying an occlusion balloon, followed by a sclerosing agent injected directly into the IGVs. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] In this process, several types of sclerosants such as EO, sodium tetradecyl sulfate (STS), 29, 30 and polidocanol are used [31] [32] [33] (Table 1) . Recently, various modified BRTO techniques had been developed, including vascular plug-assisted retrograde transvenous obliteration (PARTO) [34] [35] [36] and coil-assisted retrograde transvenous obliteration (CARTO) 37 ( Table 2) .
Indications for BRTO are IGVs with prior bleeding and highrisk IGVs with impending rupture. The latter may merit prophylactic obliteration. BRTO techniques can achieve more than 90% eradication of IGVs. 38 However, BRTO has a certain risk to increase portal pressure, worsen the complications, and cause events such as bleeding from EV or ascites. Although no randomized control trials have compared BRTO techniques with other therapies, BRTO techniques are recognized as one of the first-line treatments for patients with IGVs to prevent rebleeding throughout historical modification [9] [10] [11] (Table 3) .
Traditional balloon-occluded retrograde transvenous obliteration method using ethanolamine oleate BRTO technique using EO was first introduced by Kanagawa et al. in 1994 18 and has been performed most frequently in Japan. Retention of the sclerosant within the IGVs without leaking into neither the portal nor systemic vasculature is of cardinal importance, and if failure might happen, it could result in severe complications. Indwelling occlusion balloons are often wedged in place for 4-12 h to avoid these events.
In Japan, 10% EO (i.e. Oldamine, Fuji Chemical Co., Toyama, Japan) is approved for the treatment of EVs. A mixture of 10% EO with an equal volume of contrast medium, either iopamidol or iohexol (i.e. 5% EOI), has been used for endoscopic injection sclerotherapy since 1991. Consequently, 5% EOI has been used for BRTO since the first introduction. However, for more than 20 years, 10% EO was not approved as a treatment for GVs by the Japanese government (i.e. off-label use), and the BRTO procedure was not covered by public medical insurance. Such being the case, an investigator-initiated clinical trial was conducted from 2014 to 2015 in order to obtain an additional indication approval. The trial was conducted under the International Conference on Harmonization guidelines for good clinical practice and the Japanese regulatory requirements for a new drug application. 28 This study was designed according to the traditional prevailing BRTO method and indications in Japan. Patients who were endoscopically confirmed to have IGVs, with gastrorenal shunt of caliber size larger than 8 mm, were included. Patients with high-risk condition such as Child-Pugh class-C, serum creatinine ≥ 1.5 mg/ mL, or serum albumin < 2.8 mg/dL (i.e. a high risk of hemolysis caused by EO) were excluded. Metallic coils, together with 50% glucose, ethanol, or both, were used to occlude the collateral veins, such as the inferior phrenic veins. The upper limit for the single use of 5% EO was set to 0.4 mL/kg to minimize the development of renal hemolytic disorders, thrombotic lung events, and acute Based on the results of this trial, EO was approved for IGV treatments using BRTO procedure in Japan, in 2017. The dose of 5% EOI for a single session was limited to less than 0.4 mL/kg or 30 mL/body in the approval. Following the pharmaceutical approval of EO, the BRTO procedure was covered by public medical insurance, as of April 2018.
Balloon-occluded retrograde transvenous obliteration using sclerosants other than ethanolamine oleate
Ten percent EO is approved only in Japan, and 5% EO (e.g. Ethamolin; QOL Medical, LLC, Kirkland, WA, USA) in the USA, European countries, and South Korea, for the treatment of EVs. According to the drug labels, 5% EO should be used for endoscopic injection sclerotherapy without mixing it with contrast media. In the USA and European countries, intervention radiologists are not familiar with EO. In addition to that, haptoglobin, which is an antidote against hemolytic toxic effects caused by EO, is not available in those countries. Accordingly, BRTO using sclerosants other than EO was introduced and had developed in those countries where 10% EO and haptoglobin are unavailable. 39 is commonly accepted as a standard treatment for varicose veins of lower extremities. It is known to be more effective than liquid sclerotherapy, even if the volume of use was small. 40 Sabri et al. introduced BRTO using STS foam in 2007 and reported 22 cases of the procedure in 2011. 29 In their report, STS foam was made using a combination of agents with 3:2:1 ratio of gas, 3% STS, and iodized oil. The mean value of the overall dose of STS was 300 mg (range: 30-600 mg), and the mean volume instilled was 10 mL (range: 1-20 mL). The mean of total volume of sclerosant mixture was 34.1 mL (range: 10-65 mL). Complete obliteration of IGVs was achieved in 16 out of 18 (89%) patients, and complications occurred in 3 out of 22 (14%) patients including partial thrombosis of portal vein, bacteremia, and symptomatic pulmonary embolism.
Polidocanol. Polidocanol (e.g. Aethoxysklerol; Kreussler Pharma, Wiesbaden, Germany) is another sclerosant used for BRTO. Liquid polidocanol is indicated to treat relatively smaller uncomplicated varicose veins of the lower extremities and is approved in Japan, South Korea, European countries, and the USA. Based on the randomized control trial 41 that showed foam polidocanol to be more effective than liquid polidocanol, foam polidocanol has also been approved in European countries and Japan for the same procedure but has not been approved in the USA. Therefore, BRTO using foam polidocanol off label, to treat IGVs, was introduced only in South Korea, Australia, and Japan. [31] [32] [33] Choi et al. had first introduced BRTO using polidocanol foam in 2005 and reported 16 cases of the procedure in 2010. 31 The foam was made of 3% polidocanol, room air, and contrast media, with the ratio of 1:2:1, respectively. The median amount of polidocanol was 7 mL (range: 2-24 mL). The median follow-up duration was 273 days (range: 3-1403 days). Fifteen out of 16 patients (93.8%) had achieved technical success. Rebleeding occurred in one case during follow-up. No procedurerelated mortality was observed. Clements et al. mixed 3% polidocanol with air, under the ratio of 1:1.6 out of six patients achieved complete regression at 6 weeks.
Modified balloon-occluded retrograde transvenous obliteration method
Traditional BRTO using indwelling balloon occlusion requires lengthy and higher level post-procedural monitoring and may cause complications related to balloon rupture or adverse effects related to sclerosing agents. As a result of the efforts to address these issues, modified occlusion methods such as PARTO and CARTO were developed.
Plug-assisted retrograde transvenous obliteration. Gwon et al. introduced PARTO in 2009 and reported 20 cases of the procedure in 2012. 34 Instead of using an indwelling balloon, a permanent vascular plug (e.g. Amplatzer Vascular Plug; AGA Medical, Golden Valley, MN, USA) was used to occlude the shunt. The vascular plug reduces the procedure and post-procedure monitoring duration and also removes the risk of balloon rupture, which results in systemic complications. PARTO is limited by the diameter of available plugs, which, in general, corresponds to shunt sizes up to 16-18 mm. A mixture of hand-cut gelatin sponge sheet (e.g. gelfoam; Pharmacia and Upjohn, Kalamazoo, Michigan, USA) and contrast media is administered into the IGVs because the vascular plug cannot block the liquid or foam sclerosants completely, due to its structure as being a mesh material. The fact that PARTO does not require selective embolization of efferent collateral veins in many cases is a good advantage. In a prospective multicenter study, a follow-up computed tomography, obtained within a week after PARTO, showed complete thrombosis of IGVs and portosystemic shunts in 72 out of 73 patients (98.6%). The mean procedure time from vascular plug placement to detachment was 22 min, ranging 10-84 min. Worsening of EVs was observed in four (22%) patients during the follow-up, with mean of 9.4 months post-procedure.
Coil-assisted retrograde transvenous obliteration. Lee et al. introduced CARTO in 2012 and reported 20 cases of the procedure in 2014. 37 They reported the technical success rate of 100%. The mean procedure time from venous access to the end of procedure (removal of sheath and initiation of venotomy hemostasis with manual compression) was 2.82 ± 0.56 h. Worsening of EVs (with no bleeding) and ascites/hydrothorax was noted in five patients (25%) during the follow-up period of 384 ± 154 days. One patient died at 24 days after the CARTO due to systemic and portal venous thrombosis and multi-organ failure.
Coils and gelatin sponge slurry were used instead of using indwelling balloons and sclerosants. CARTO would be advantageous if the shunt size, shunt angle, or vessel tortuosity were not conducive to the use of a balloon or vascular plugs. CARTO can be performed in larger shunts, up to 25-30 mm in diameter. However, multiple detachable coils (average 11.1 ± 5.3, range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] are indispensable to complete the occlusion of shunt vein. CARTO may be costlier in cases that require multiple detachable coils compared with those with use of a single vascular plug.
Comparison between various sclerosants and balloon-occluded retrograde transvenous obliteration techniques
To the best of our knowledge, no prospective comparative trial between the BRTO procedures with the use of different sclerosants or occlusion methods had been conducted so far. Hence, we have no choice but to evaluate retrospective comparison study or historically compare the reported literature. Regarding conventional BRTO procedure, an indwelling inflated balloon requires a longer duration of the procedure, more hospital resources, and more medical staffs. Balloon rupture may fail the procedure, and sclerosants may cause adverse events. The sclerosing agents, especially EO, are associated with some of the severe complications due to its hemolytic effect, including pulmonary edema, disseminated intravascular coagulation, portal vein thrombosis, and renal dysfunction. Accordingly, BRTO using EO is covered by Japanese public insurance with limitation; only the procedures performed at institutes, where emergency medical care systems and medical staffs are sufficient, will be covered. On the other hand, the adverse effects caused by STS and polidocanol are likely to be minor compared with EO; therefore, the use of these sclerosants does not require prophylactic administration of haptoglobin for hemolytic disorders prevention. Additionally, the use of foam sclerosants can reduce the injection volume required to fill the GVs and shunt, thus reducing the chance of adverse effects even more.
Chu et al. reported that BRTO using STS (a mixture of 3% STS, contrast media, and room air with 1:1:2 ratio, n = 83) had longterm outcomes comparable with BRTO using EO (5% EO mixed with iodized oil with 5:1 ratio, n = 53) performed on GVs, in a retrospective study. 42 The cumulative 1-, 3-, and 5-year recurrence rates of GVs were 3.8%, 9.4%, and 9.4% in the BRTO with EO and 1.3%, 2.5%, and 3.8% in the BRTO with STS, respectively.
Itou et al. reported the retrospective comparisons of BRTO using polidocanol foam (3% polidocanol and air mixture with 1:4 ratio, n = 21) and 5% EO (n = 20). 33 The median follow-up periods were 39.5 months (mean 59.2 ± 54.4 months; range 1-135 months) for the EO group and 34 months (mean 31.1 ± 25 months, range 1-97 months) for the polidocanol foam group. Complete obliteration was confirmed in all but one case of early recanalization after treating with polidocanol foam. One patient died of acute respiratory distress syndrome after treating with EO. The total sclerosant volume was significantly lower in 3% polidocanol foam group (13.5 ± 6.8 mL) than in 5% EO group (30.6 ± 15.6 mL) (P < 0.01). The levels of aspartate aminotransferase (P < 0.01), total bilirubin (P < 0.01), and indirect bilirubin (P < 0.05), which were primarily associated with hemolysis, had increased on postoperative day 1 in the EO group, and the trend of increase was significantly greater compared with the polidocanol foam group. The number of patients presented with chest and epigastric pain was significantly lower in the polidocanol foam group (1/21) than in the EO group (4/20) (P < 0.05).
The advantage of replacing the indwelling balloon for permanent vascular plugs or coils is that it can reduce post-procedure monitoring duration and related staffs. Another advantage of PARTO and CARTO is that gelatin sponge can replace the harmful sclerosants. However, in a retrospective study, 35 PARTO was associated with frequent recurrence of GVs (32.8%; 4/18 cases) during 1-year follow-up in marked contrast to BRTO with EO (3.1%; 2/34 cases) or STS foam (0%; 0/18 cases). Frequent recurrence of IGVs probably occurred because the gelatin sponge was able to embolize the GVs only temporary and did not have a sufficient effect to destruct the endothelial cell.
On the contrary, BRTO using EO had been performed for more than 2 decades, and reports on long-term efficacy (e.g. complete regression and non-bleeding) have already been revealed. 22, 23, 26, 27 The relationship between the long-term clinical outcome and shunt occlusion after the practice of BRTO using EO was reported as well. 27 Even among the patients with incomplete thrombosis after 1 week, complete thrombosis was observed after 3 months, without adding any therapeutic sessions. 28 From these findings, complete thrombosis after BRTO with EO, which causes endothelial damage, can be considered as a reasonable surrogate to predict the long-term efficacy to prevent GV bleeding. It is yet unclear if gelatin sponge, a temporary embolic material, can achieve a long-term thrombotic effect and prevent rebleeding after the PARTO or CARTO procedures.
Conclusions
The initial control of active bleeding from IGVs will be performed by balloon tamponade, endoscopic variceal ligation, endoscopic variceal obturation with tissue adhesive such as N-butyl-cyanoacrylate, or conservative treatment such as transfusion. When the bleeding control was achieved successfully, then, BRTO and modified BRTO techniques should be considered electively in order to prevent rebleeding from IGVs, if those patients had large portsystemic shunt and did not have concurrent high-risk conditions. Generally, doctors should choose BRTO techniques familiar with them and use sclerosant that are approved for use in their country. Although PARTO and CARTO seem to be safer and easier to perform in terms of the balloon rupture risk, the high adverse event rate caused by EO, and procedure time, compared with the traditional BRTO with EO, data of PARTO and CARTO are limited to evaluate the long-term efficacy.
Long-term prospective studies are needed to allow further comparison among the use of various sclerosant agents such as EO, STS, and polidocanol; comparison among the various occlusion methods such as the methods with an indwelling balloon, PARTO, or CARTO; and furthermore, comparison among the multiple combinations of various sclerosant and occlusion methods.
